CEACAM5
Cell adhesion molecule CEACAM5
As of the edition of 20 October 2026, CEACAM5 (cell adhesion molecule CEACAM5, UniProt P06731) has 8 drugs tested at it and 8 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06731
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Skin and connective tissue; Nervous system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 33
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 5 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tusamitamab ravtansine | Stopped | Phase 3 | none listed |
| SGM-101 | Active | Phase 3 | none listed |
| Cibisatamab | Stopped | Phase 2 | none listed |
| Labetuzumab | Stopped | Phase 2 | none listed |
| Labetuzumab govitecan | Stopped | Phase 2 | none listed |
| MEDI-565 | Stopped | Phase 1 | none listed |
| NEO-201 | Went quiet | Phase 2 | none listed |
| Arcitumomab | Marketed | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Engaged | 1 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Sanofi | Route A |
| Roche | Route A |
| Innovent Biologics | Route A |
The other 5 companies at CEACAM5
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at CEACAM5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.